← All candidates
52 insider filings on record.
52 filings on record.
TXG10x Genomics, Inc.
NasdaqGS · Healthcare · $9.47B
$72.68
-2.30% today
52 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 26 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$9.47B
Float
118.2M
98% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
357.4
Price / sales
15.3
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
47 more transactions on Pro →Context
Wall St
$51.00 avg target
-29.8% vs today · 14 analysts · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
4 of 4 quarters beat
Q2 '26$0.03 act+$0.04
Q1 '26$0.07 act+$0.13
Q4 '25$0.07 act+$0.11
Q3 '25−$0.02 act+$0.05
Coverage
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?Zacks · 1w ago10x Genomics Needs "Meaningful' Growth in Single-Cell Business, RBC SaysMT Newswires · 2w agoTXG Stock Down Despite Patent Verdict Win Against Parse BiosciencesZacks · 2w ago10x Genomics (TXG) Sees Strong Early Orders for New Atera PlatformInsider Monkey · 4w ago
The file stays open
52 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice